PTAB Axes Antecip IP, Rejects Its Printed Publication Stance
The Patent Trial and Appeal Board has invalidated three Antecip Bioventures pain treatment patents, shooting down its argument that German rival Grunenthal GmbH didn't do enough at the institution stage to...To view the full article, register now.
Already a subscriber? Click here to view full article